Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.39 |
| ▸ | S100A10 | P60903 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665571 | 0.83 | CYP2A6 (0.38) | CYP3A4TSHRMAPK1CYP2C9CYP2C19 | |
| SCHEMBL9649049 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL10813732 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL9647766 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL9485438 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL9485453 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL9647870 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| 4,4'-Thiodianiline SCHEMBL49068 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL9649030 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT | |
| SCHEMBL1098379 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1PDE7AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | CYP3A4 1809/4885TSHR 3551/4885MAPK1 1/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | CYP3A4 1809/4885TSHR 3551/4885MAPK1 1/4885 |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BRAF, RAF1, ARAF | CYP3A4 2650/4885TSHR 3368/4885MAPK1 137/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | CYP3A4 2132/4885TSHR 3511/4885MAPK1 2/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | CYP3A4 2733/4885TSHR 3707/4885MAPK1 1/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | CYP3A4 4030/4885TSHR 2259/4885MAPK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.